Un essai clinique ouvre la voie à un nouveau traitement révolutionnaire de la myasthénie grave
Un nouveau médicament contre cette maladie neuromusculaire rare a été approuvé par la FDA.
Biopharmaceutical company UCB recently shared important news that may affect those living with generalized myasthenia gravis (gMG): they’ve received approval from the U.S. Food and Drug Administration (FDA) for a groundbreaking treatment called ZILBRYSQ® (zilucoplan).
The FDA approved Zilucoplan based on data from a study called RAISE, published in The Lancet Neurology in May 2023. The study showed that Zilucoplan offered rapid and significant benefits to a wide range of gMG patients.
Know Rare est fier d'avoir soutenu ce développement en recrutant des patients pour l'étude RAISE. L'une des principales missions de Know Rare est d'aider les patients atteints de maladies rares à participer à des essais cliniques tels que celui-ci, qui peuvent avoir un impact positif sur leur bien-être. Si vous souhaitez en savoir plus sur les essais cliniques et les études susceptibles de vous intéresser, contactez-nous à l'adresse support@knowrare.com.
PLUS D'INFORMATIONS SUR ZILBRYSQ® (zilucoplan) :
Zilucoplan is a self-administered once-daily therapy for adults with generalized myasthenia gravis that works by inhibiting complement-mediated damage to the neuromuscular junction, which is where your nerves and muscles communicate. This helps to prevent the damage and weakness caused by myasthenia gravis. Unlike other treatments that need to be given intravenously, Zilucoplan is a subcutaneous (SC) peptide that you can inject under your skin. These developments mean that patients can take zilucoplan from their homes, reducing the need for frequent hospital visits.
